The Oncology Institute, Inc. (DFPH)

The Oncology Institute, Inc. is a network of cancer treatment centers operating throughout the United States, delivering outpatient oncology and hematology care to patients with blood cancers and solid tumors. The company does not own hospitals; instead, it operates stand-alone and hospital-based infusion centers under partnership agreements with health systems and hospital networks. Its business depends on the steady flow of patients needing chemotherapy, immunotherapy, targeted therapy, and supportive care—demand that is driven by incidence rates that change slowly, but reimbursement that can shift sharply when insurance companies revise payment schedules or shift the mix of patient types seeking treatment.

A specialty practice in transition

Oncology Institute was founded in 2009 as a single practice in California and grew by opening new centers and acquiring existing oncology practices across multiple states. The company went public in 2021 with a vision of building a national network of outpatient cancer care franchises. Unlike large health systems, Oncology Institute does not own the buildings or hold all the patient records; instead, it operates under long-term service agreements with hospital systems and freestanding imaging centers, capturing a professional-services fee for providing the oncology physicians, nurses, infusion nurses, and care coordination that the locations need. The model resembles staffing or medical management rather than traditional medical practice ownership.

This asset-light structure allows the company to scale without needing to buy or build expensive infrastructure. However, it also means Oncology Institute is vulnerable to the decisions of its partners—if a hospital system wants to bring oncology in-house, renegotiates terms unfavorably, or terminates an agreement, the company loses that revenue stream. The quality of relationships with major partners, and the stickiness of those partnerships, is therefore central to the business.

How demand and reimbursement flow together

Oncology Institute’s revenue comes almost entirely from treating patients—the fees paid by insurance companies (Medicare, Medicaid, and commercial plans) for delivering chemotherapy and related care. The company does not charge patients directly; insurers cover the vast majority of the cost. This dependence on third-party reimbursement means the company earns less when insurance companies reduce payment rates, when fewer patients receive chemotherapy (for instance, because new oral therapies replace infusions), or when the mix of patients shifts toward lower-reimbursed populations such as Medicare and Medicaid.

Cancer incidence, though serious, is relatively stable year to year. But the path that patients take through treatment is not. Over the past decade, the oncology field has seen a gradual shift from intravenous chemotherapy to oral pills and immunotherapies administered as infusions on longer intervals. Each shift changes the number of infusion visits a typical patient needs and thus the revenue a center collects per patient. Patients switching to pills—drugs they take at home—reduce the number of visits to Oncology Institute’s centers. This structural change is partly offset by new indications (cancers for which infusions are approved) and by combination therapies (which increase the number of drugs given), but the long-term trajectory of mix and utilization is something the company cannot control.

The cyclical pressure: insurance and cash flow

Oncology Institute’s profitability is squeezed during downturns in two ways. First, insurance companies tighten reimbursement rates and scrutinize every claim when they face cost pressure. A recession that sends employment down also sends uninsured and underinsured patients into the system; those patients often pay through Medicaid, which reimburses at lower rates than commercial insurance. Second, the company runs on very tight cash margins—the fees it receives from insurers must cover salaries for a large medical staff, rent or service fees to hospital partners, and supplies. If insurance payments are delayed or reduced, the company quickly feels the strain because it cannot easily reduce payroll or renegotiate partner fees in the short term. During a prolonged economic downturn, Oncology Institute would face both lower reimbursement rates and a higher proportion of lower-paying patients, while its cost structure remains relatively fixed. This is the classic vulnerability of a specialty medical services business.

Conversely, in boom times when employment is high and commercial insurance is prevalent, reimbursement rates hold firm, patient volume is stable, and the company’s margins recover. However, even in good years, Oncology Institute is not a growth story in the sense that revenue per center is not expanding rapidly—most growth comes from opening new centers, which requires capital and involves lag time before they mature.

What to watch

Readers researching Oncology Institute should begin with its annual 10-K filing (SEC CIK 0001799191), which details the company’s center count, revenue per location, and the top hospital partners that account for significant portions of revenue. The quarterly earnings releases focus on metrics like revenue per center, patient volume trends, and any gains or losses of major partner relationships. A reader should track whether new centers are opening, whether mature centers are holding their patient volumes, and what the company says about reimbursement pressure from major insurers. Insurance rate cuts or significant patient volume declines are warning signs; sustained growth in patient volume and stable reimbursement are what the business needs to succeed. Any material loss of a major hospital partner is a substantial adverse event that would reshape the company’s trajectory.